ATLANTA -
- The Ross Summit 2009 to focus on new patient data supporting the Ross heart reconstruction procedure and the use of SynerGraft(R) processed human heart valves in the Ross Procedure
More than 130 cardiovascular surgeons from approximately 30 countries are scheduled to attend the second annual global Ross Summit, a two-day surgical congress focused on the highly complex Ross Procedure, which is performed on up to 1,500 individuals globally each year — a number that is expected to increase as survival data become more widely published.
To view the multimedia assets associated with this release, please click news.prnewswire.com/viewrelease.aspx?STORY=MTM4
CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, will convene the summit at its corporate headquarters training facility in suburban Atlanta Sept. 25-26. The forum provides an opportunity to review and discuss current peer-reviewed data from the world’s experts relating to the survival advantage of the Ross Procedure and technical nuances required to perform the operation successfully.
The Ross Procedure is a type of specialized aortic valve surgery in which the patient’s diseased aortic valve is replaced with his or her own pulmonary valve. The pulmonary valve can then be replaced with a cryopreserved human pulmonary valve.
Pioneered in 1967, by Mr. Donald N. Ross, FRCS in London, U.K., the procedure is a complex surgical technique that is performed by surgeons skilled in reconstructive cardiac surgery due to the level of technical expertise required to execute the procedure.
“In children, young adults and in active older adults, the Ross Procedure offers several advantages over other traditional aortic valve replacement options,” said Dr. William Northrup III, vice president of physician relations and education at CryoLife. “The most important advantage is growing evidence of improved long-term survival over other valve replacement options. The procedure is also attractive because patients who undergo the procedure do not have to take long-term, blood-thinning medications after surgery. This is particularly appealing to women of child-bearing age and athletes.”
“However, the Ross Procedure requires very specific surgical expertise to achieve predictable, long-lasting results, and The Ross Summit was created to foster data exchange to provide a well-rounded point of view in addition to offering critical procedural training.”
A decellularized human pulmonary heart valve, CryoValve(R) SG, processed using CryoLife’s SynerGraft(R) technology, was cleared by the FDA in February 2008 for use in cardiac reconstruction procedures, which includes the Ross Procedure.
Led by Professor Sir Magdi Yacoub, FRS, FRCS, of Imperial College’s Heart Science Center in London in tandem with Dr. Northrup, the Ross Summit will have a faculty of more than 30 world-renowned cardiovascular surgeons, who will present clinical data on heart reconstruction surgery at their respective clinics. The summit includes two afternoons of hands-on instruction in the various techniques of cardiac reconstruction. A full faculty list and summit agenda can be found at www.TheRossSummit.org.
“The summit has doubled in attendance since our inaugural session in fall 2008,” said Steven G. Anderson, chairman, president and CEO of CryoLife. “We’re thrilled with the registration numbers to date and look forward to an informative, dynamic summit.”
About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company’s CryoValve(R) SG pulmonary human heart valve, processed using CryoLife’s proprietary SynerGraft(R) technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed or malfunctioning native or prosthetic pulmonary valves. The Company’s BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company’s BioFoam(R) Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. BIOGLUE Aesthetic(TM) Medical Adhesive is CE marked in the European Community for periosteal fixation following endoscopic browplasty (brow lift) in reconstructive plastic surgery and is distributed by a third party for this indication. CryoLife distributes HemoStase(TM), a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the European Community and Canada for cardiac, vascular, and general surgery, subject to certain exclusions.
Statements made in this press release or in the embedded video that look forward in time or that express management’s beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those regarding the expected increases in the number of Ross Procedures, expected mortality rates of patients undergoing the Ross Procedure with an experienced surgeon, expected incidents of surgical reinterventions in patients undergoing the Ross Procedure, and expected increased support for better survival rates for patients undergoing Ross Procedures than other valve replacement options. These future events may not occur as and when expected, if at all, and, together with the Company’s business, are subject to various risks and uncertainties. These risks and uncertainties are detailed in CryoLife’s Securities and Exchange Commission filings, including CryoLife’s Form 10-K filing for the year ended December 31, 2008, our Form 10-Q for the quarter ended March 31, 2009, our Form 10-Q for the quarter ended June 30, 2009, and the Company’s other SEC filings. The Company does not undertake to update its forward-looking statements.
For additional information about the company, visit CryoLife’s Web site: www.cryolife.com.
Media Contacts: D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: +1-770-419-3355 Dana Hartline Vice President Edelman Phone: +1-404-262-3000
Source: CryoLife, Inc.
D. Ashley Lee, Executive Vice President, Chief Financial Officer and Chief Operating Officer of CryoLife, Inc., +1-770-419-3355; or Dana Hartline, Vice President of Edelman for CryoLife, Inc., +1-404-262-3000; Video: http://news.prnewswire.com/viewrelease.aspx?STORY=MTM4
Related Press Releases
MitraClip(R) Therapy Data Demonstrate Significant Left Ventricular Reverse Remodeling in Patients With Sustained Reduction of Mitral RegurgitationSeptember 21st, 2009 SAN FRANCISCO -
- 12-Month Data Presented at TCT 2009 Show Significant Improvement in Left Ventricular Function with no Change in Annular Dimensions
Sustained reduction of mitral regurgitation following mitral valve repair with the MitraClip(R) system in patients with degenerative mitral regurgitation (DMR) or functional mitral regurgitation (FMR) led to heart function improvements, according to 12-month data from a subset of the initial registry cohort of the EVEREST (Endovascular Valve Edge-to-Edge REpair STudy) studies presented today at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco. The data were presented today by Scott Lim, M.D., interventional cardiologist at the University of Virginia Medical Center and one of the EVEREST trial investigators.
Data Show Long-Term Mechanical Integrity of MitraClip(R) and Complete Healing Following Implantation of the Device for Mitral Valve RepairSeptember 21st, 2009 SAN FRANCISCO -
- Results of Histopathology and Mechanical Integrity Analysis of MitraClip(R) Devices Presented at TCT 2009
The mechanical integrity of the MitraClip(R) device for repair of the mitral valve was maintained for up to five years and with complete healing, according to a subset of data from the EVEREST (Endovascular Valve Edge-to-Edge REpair STudy) study presented today at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco. The data also show complete fibrous encapsulation of the MitraClip device with organized, endocardial tissue growth demonstrating complete healing and incorporation of the implant within the native mitral valve.
Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual SummitSeptember 20th, 2009 ATLANTA -
- Growing Outcomes Evidence Spurs Renewed Interest in Unique Heart Valve Procedure
CryoLife, Inc. (NYSE: CRY) -- Elite cardiovascular surgeons from around the world will travel to suburban Atlanta this week for the two-day Ross Summit to review and discuss current peer-reviewed data relating to the survival advantage of the Ross Procedure and to practice the technical nuances required to perform this heart surgery successfully.
Ongoing Progress of MitraClip(R) Therapy Highlighted at TCT 2009September 14th, 2009 MENLO PARK, California -
- European Commercial Pace Continues to Grow with 200 Patients Treated
- Evalve Reaches U.S. Clinical Trial Milestone
The upcoming Transcatheter Cardiovascular Therapeutics (TCT) Conference, to take place in San Francisco from September 21-25, will serve as a backdrop for the presentation of EVEREST registry clinical results of the MitraClip(R) therapy for patients with mitral regurgitation (MR).
MitraClip(R) Therapy Introduced in AustriaSeptember 8th, 2009 MENLO PARK, California -
- Use of the MitraClip(R) System Continues to Expand in Europe
Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, today announced treatment of the first group of patients with the MitraClip(R) system at the Elisabethinen Krankenhaus, Linz, Austria. The MitraClip(R) system is the only medical device commercially available in the European Union which provides a non-surgical mitral valve repair option for patients suffering from the effects of functional and degenerative mitral regurgitation (MR).
Computer-assisted Surgery: European Hotspot Opens in GermanyAugust 25th, 2009 LEIPZIG, Germany - Surgery in Full HD: Leipzig is now home to the future of precise, efficient and safe high-tech surgery. The International Reference and Development Centre for Surgical Technology (IRDC) is implementing an innovative, comprehensive approach in specialty surgery.
Q-Med, Industry Leading Medical Device Company, Responds to Survey by the British Association of Aesthetic Plastic SurgeonsJune 9th, 2009 LONDON - Information released this week by the British Association of Aesthetic Plastic Surgeons (BAAPS) highlights their concerns over permanent fillers. Q-Med, the leading Swedish medical device company which has developed and produced Restylane(R) and Macrolane(TM), confirms that all of its products are temporary.
MitraClip(R) Therapy Data Demonstrate Clinical Benefit in High-Risk Patients With Mitral RegurgitationMay 19th, 2009 BARCELONA, Spain - EVEREST High-Risk Registry Data Show Improved Symptomatic Status, Cardiac Function and Reduced rate of Hospitalization for Congestive Heart Failure in both Functional and Degenerative MR Patient Populations
Results show percutaneous mitral repair using the MitraClip(R) system in symptomatic high-risk surgical patients with either functional mitral regurgitation (FMR) or degenerative mitral regurgitation (DMR) improves patient clinical status. The results from the 78 patient EVEREST II High Risk Registry demonstrated improvement in left ventricular function and reduced hospitalization for congestive heart failure for both MR groups at twelve months.
First 100 Patients Treated in Europe with the MitraClip(R) System for Percutaneous Mitral RepairMay 13th, 2009 MENLO PARK, California - Use of the MitraClip(R) Therapy Continues to Expand in Europe
Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced today that the first 100 patients have been treated with the MitraClip(R) system in Europe. Clinical results to date underscore the acute clinical benefit for patients, demonstrate the potential for reduced hospital stays and improved quality-of-life for patients.
Simbionix Increases Product Offerings for OB/GYN PhysiciansMarch 10th, 2009 CLEVELAND and ZURICH, Switzerland - Simbionix and VirtaMed Have Joined Forces to Provide OB/GYN Surgeons
the Most Advanced Training System for Endoscopic Surgery
- The New VirtaMed HystSim(TM) Simulator Adds Hysteroscopy to Simbionix'
Impressive Line of Medical Simulation and eLearning Products
Simbionix, the world's leading developer of medical simulation systems,
and VirtaMed, a Swiss medical engineering company, announced today a global
collaboration agreement. Simbionix will exclusively distribute, market, and
provide service for the VirtaMed HystSim, an advanced virtual reality
hysteroscopy simulator.
Related News
RI hospitals adopt same surgical protocol to help traveling docs, reduce potential errorsJune 30th, 2009 RI hospitals to announce new surgical protocolPROVIDENCE, R.I. — Surgeons in Rhode Island will start following the same procedures before surgeries, no matter which hospital they are working in.
'Two-in-one' boob job uses unwanted body fatSeptember 14th, 2009 LONDON - Here's some news that will bring double joy to women: a "two in one" boob job technique that uses unwanted fat from other parts of the body has been developed. The breast enlargement operation takes excess fat from the thighs and stomach and moves it to the bust.
Surgeons pull out healthy kidney through donor's vaginaFebruary 2nd, 2009 WASHINGTON - Surgeons at Johns Hopkins have successfully pulled out a healthy kidney through a small incision at the back of the donor's vagina, in a historic first ever operation. 'The kidney was successfully removed and transplanted into the donor's niece, and both patients are doing fine,' said Robert Montgomery, chief of the transplant division at Johns Hopkins University School of Medicine (JHUSM), who led the operation.
What is beating-heart bypass surgery?January 23rd, 2009 NEW DELHI - The beating-heart bypass surgery that Prime Minister Manmohan Singh underwent here Saturday is considered the safest for elderly patients who have had a bypass surgery earlier and also have other ailments, say cardiologists. In an open-chest, beating-heart bypass procedure, surgeons make an incision through the breastbone to access the heart, which is not stopped during the surgery.
Australia's oldest man and last remaining Australian to serve in WWI dies at 110June 3rd, 2009 Australia's oldest man, WWI vet, dies at 110SYDNEY — John "Jack" Ross, Australia's oldest man and the last remaining Australian to serve in World War I, died Wednesday, Veterans' Affairs Minister Alan Griffin said. He was 110. Ross died in his sleep at a nursing home in the Victoria state city of Bendigo.
PM's heart surgeon was among highest taxpayersJanuary 22nd, 2009 NEW DELHI - Ramakant Panda, who will perform heart bypass surgery on Prime Minister Manmohan Singh Saturday, has received a prestigious national award for being among the country's highest taxpayers, his profile posted on the Asian Heart Institute of which he is the vice chairman, says. The Central Board of Direct Taxes awarded Panda a Rashtriya Samman (National Honour) for being one of the highest taxpayers during the assessment years 1994-95 to 1998-99.
Russell Brand, Jonathan Ross now 'want to conquer the world'April 22nd, 2009 LONDON - Pranksters Russell Brand and Jonathan Ross have teamed up again and now want to conquer the world. The two pranksters had faced much heat after the Andrew Sachs scandal, which led to Brand's resignation from the BBC in October after he boasted about sleeping with the 78-year-old's granddaughter.
'Two for one' breast boosting technique not as viable as it seemsSeptember 16th, 2009 LONDON - A technology that was claimed as the ultimate solution to give a boost to women's breasts by using fat removed from thighs is not viable as it seems, say experts. Mel Graham, chairman of the Harley Medical Group, recently claimed that the "two for one" procedure could extract excess fat from where it was not wanted - the belly, hips or thighs - and relocate it to the bust.
Dasmunsi being mobilised on wheelchair: hospitalApril 8th, 2009 NEW DELHI - Congress leader and central minister Priya Ranjan Dasmunsi, who has been in hospital for almost six months, is now being mobilised on a wheelchair every day, the Indraprastha Apollo Hospital here said Tuesday. 'Priya Ranjan Dasmunshi remains neurologically status quo and off life support,' it said.
Burkina Faso's `pleasure hospital' offers women sexual hopeMay 21st, 2009 Bobo-DIOULASSO - In the dusty town of Bobo-Dioulasso in western Burkina Faso, young women in brightly-coloured dresses watch construction workers mix cement in the afternoon sun. As the workmen haul bricks across the building site, the women whisper excitedly.
